Literature DB >> 23814019

Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma.

Scott R P McDonnell1, Steven R Hwang, Delphine Rolland, Carlos Murga-Zamalloa, Venkatesha Basrur, Kevin P Conlon, Damian Fermin, Thomas Wolfe, Alexander Raskind, Chunhai Ruan, Jian-Kang Jiang, Craig J Thomas, Cory M Hogaboam, Charles F Burant, Kojo S J Elenitoba-Johnson, Megan S Lim.   

Abstract

The mechanisms underlying the pathogenesis of the constitutively active tyrosine kinase nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) expressing anaplastic large cell lymphoma are not completely understood. Here we show using an integrated phosphoproteomic and metabolomic strategy that NPM-ALK induces a metabolic shift toward aerobic glycolysis, increased lactate production, and biomass production. The metabolic shift is mediated through the anaplastic lymphoma kinase (ALK) phosphorylation of the tumor-specific isoform of pyruvate kinase (PKM2) at Y105, resulting in decreased enzymatic activity. Small molecule activation of PKM2 or expression of Y105F PKM2 mutant leads to reversal of the metabolic switch with increased oxidative phosphorylation and reduced lactate production coincident with increased cell death, decreased colony formation, and reduced tumor growth in an in vivo xenograft model. This study provides comprehensive profiling of the phosphoproteomic and metabolomic consequences of NPM-ALK expression and reveals a novel role of ALK in the regulation of multiple components of cellular metabolism. Our studies show that PKM2 is a novel substrate of ALK and plays a critical role in mediating the metabolic shift toward biomass production and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23814019      PMCID: PMC3739039          DOI: 10.1182/blood-2013-01-482026

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  ANTIBIOTIC STUDIES. II. INHIBITION OF PHOSPHORYL TRANSFER IN MITOCHONDRIA BY OLIGOMYCIN AND AUROVERTIN.

Authors:  H A LARDY; J L CONNELLY; D JOHNSON
Journal:  Biochemistry       Date:  1964-12       Impact factor: 3.162

2.  Small molecule activation of PKM2 in cancer cells induces serine auxotrophy.

Authors:  Charles Kung; Jeff Hixon; Sung Choe; Kevin Marks; Stefan Gross; Erin Murphy; Byron DeLaBarre; Giovanni Cianchetta; Shalini Sethumadhavan; Xiling Wang; Shunqi Yan; Yi Gao; Cheng Fang; Wentao Wei; Fan Jiang; Shaohui Wang; Kevin Qian; Jeff Saunders; Ed Driggers; Hin Koon Woo; Kaiko Kunii; Stuart Murray; Hua Yang; Katharine Yen; Wei Liu; Lewis C Cantley; Matthew G Vander Heiden; Shinsan M Su; Shengfang Jin; Francesco G Salituro; Lenny Dang
Journal:  Chem Biol       Date:  2012-09-21

3.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.

Authors:  C A Griffin; A L Hawkins; C Dvorak; C Henkle; T Ellingham; E J Perlman
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

4.  Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells.

Authors:  Jun Fan; Taro Hitosugi; Tae-Wook Chung; Jianxin Xie; Qingyuan Ge; Ting-Lei Gu; Roberto D Polakiewicz; Georgia Z Chen; Titus J Boggon; Sagar Lonial; Fadlo R Khuri; Sumin Kang; Jing Chen
Journal:  Mol Cell Biol       Date:  2011-10-03       Impact factor: 4.272

5.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.

Authors:  D Bischof; K Pulford; D Y Mason; S W Morris
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

6.  Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.

Authors:  Willi Woessmann; Christina Peters; Meike Lenhard; Birgit Burkhardt; Karl-Walter Sykora; Dagmar Dilloo; Bernhard Kremens; Peter Lang; Monika Führer; Thomas Kühne; Reza Parwaresch; Wolfram Ebell; Alfred Reiter
Journal:  Br J Haematol       Date:  2006-04       Impact factor: 6.998

7.  Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.

Authors:  Taro Hitosugi; Sumin Kang; Matthew G Vander Heiden; Tae-Wook Chung; Shannon Elf; Katherine Lythgoe; Shaozhong Dong; Sagar Lonial; Xu Wang; Georgia Z Chen; Jianxin Xie; Ting-Lei Gu; Roberto D Polakiewicz; Johannes L Roesel; Titus J Boggon; Fadlo R Khuri; D Gary Gilliland; Lewis C Cantley; Jonathan Kaufman; Jing Chen
Journal:  Sci Signal       Date:  2009-11-17       Impact factor: 8.192

8.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

9.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Authors:  James G Christensen; Helen Y Zou; Maria E Arango; Qiuhua Li; Joseph H Lee; Scott R McDonnell; Shinji Yamazaki; Gordon R Alton; Barbara Mroczkowski; Gerrit Los
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

10.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.

Authors:  Dimitrios Anastasiou; Yimin Yu; William J Israelsen; Jian-Kang Jiang; Matthew B Boxer; Bum Soo Hong; Wolfram Tempel; Svetoslav Dimov; Min Shen; Abhishek Jha; Hua Yang; Katherine R Mattaini; Christian M Metallo; Brian P Fiske; Kevin D Courtney; Scott Malstrom; Tahsin M Khan; Charles Kung; Amanda P Skoumbourdis; Henrike Veith; Noel Southall; Martin J Walsh; Kyle R Brimacombe; William Leister; Sophia Y Lunt; Zachary R Johnson; Katharine E Yen; Kaiko Kunii; Shawn M Davidson; Heather R Christofk; Christopher P Austin; James Inglese; Marian H Harris; John M Asara; Gregory Stephanopoulos; Francesco G Salituro; Shengfang Jin; Lenny Dang; Douglas S Auld; Hee-Won Park; Lewis C Cantley; Craig J Thomas; Matthew G Vander Heiden
Journal:  Nat Chem Biol       Date:  2012-10       Impact factor: 15.040

View more
  25 in total

Review 1.  Nutrition and metabolic correlates of obesity and inflammation: clinical considerations.

Authors:  Amy R Johnson; Liza Makowski
Journal:  J Nutr       Date:  2015-04-01       Impact factor: 4.798

Review 2.  Metabolomic and molecular insights into sickle cell disease and innovative therapies.

Authors:  Morayo G Adebiyi; Jeanne M Manalo; Yang Xia
Journal:  Blood Adv       Date:  2019-04-23

3.  Bacterial nutrient foraging in a mouse model of enteral nutrient deprivation: insight into the gut origin of sepsis.

Authors:  Matthew W Ralls; Farokh R Demehri; Yongjia Feng; Sasha Raskind; Chunhai Ruan; Arno Schintlmeister; Alexander Loy; Buck Hanson; David Berry; Charles F Burant; Daniel H Teitelbaum
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-01       Impact factor: 4.052

Review 4.  Protein networks and activation of lymphocytes.

Authors:  Ynes A Helou; Arthur R Salomon
Journal:  Curr Opin Immunol       Date:  2015-02-14       Impact factor: 7.486

5.  Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

Authors:  Yael P Mossé; Stephan D Voss; Megan S Lim; Delphine Rolland; Charles G Minard; Elizabeth Fox; Peter Adamson; Keith Wilner; Susan M Blaney; Brenda J Weigel
Journal:  J Clin Oncol       Date:  2017-08-08       Impact factor: 44.544

6.  Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma.

Authors:  Steven R Hwang; Carlos Murga-Zamalloa; Noah Brown; Johnvesly Basappa; Scott Rp McDonnell; Veronica Mendoza-Reinoso; Venkatesha Basrur; Ryan Wilcox; Kojo Elenitoba-Johnson; Megan S Lim
Journal:  Lab Invest       Date:  2017-04-17       Impact factor: 5.662

7.  Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.

Authors:  Amit Dipak Amin; Soumya S Rajan; Winnie S Liang; Praechompoo Pongtornpipat; Matthew J Groysman; Edgar O Tapia; Tara L Peters; Lori Cuyugan; Jonathan Adkins; Lisa M Rimsza; Yves A Lussier; Soham D Puvvada; Jonathan H Schatz
Journal:  Cancer Res       Date:  2015-05-27       Impact factor: 12.701

8.  ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3.

Authors:  Mengnan Hu; Ruoxuan Bao; Miao Lin; Xiao-Ran Han; Ying-Jie Ai; Yun Gao; Kun-Liang Guan; Yue Xiong; Hai-Xin Yuan
Journal:  Oncogene       Date:  2022-09-05       Impact factor: 8.756

Review 9.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 10.  ALK-driven tumors and targeted therapy: focus on crizotinib.

Authors:  Carlos Murga-Zamalloa; Megan S Lim
Journal:  Pharmgenomics Pers Med       Date:  2014-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.